| 11.33 -1.09 (-8.78%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.55 | 1-year : | 16.99 |
| Resists | First : | 12.46 | Second : | 14.55 |
| Pivot price | 11.48  |
|||
| Supports | First : | 10.8 | Second : | 9.78 |
| MAs | MA(5) : | 11.89 |
MA(20) : | 11.12 |
| MA(100) : | 10.52 |
MA(250) : | 9.52 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 81.8 |
D(3) : | 85.3 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 12.57 | Low : | 6.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TLX ] has closed above bottom band by 44.8%. Bollinger Bands are 48.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.36 - 11.41 | 11.41 - 11.46 |
| Low: | 11.05 - 11.12 | 11.12 - 11.16 |
| Close: | 11.23 - 11.34 | 11.34 - 11.41 |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Fri, 21 Aug 2026
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened - MarketBeat
Thu, 20 Aug 2026
Telix Pharmaceuticals: Strong Revenue Growth, With Upcoming Resubmission for Zircaix - Morningstar
Thu, 20 Aug 2026
Telix Pharmaceuticals (TLX) swings to H1 profit as revenue jumps - Stock Titan
Thu, 20 Aug 2026
Telix Pharmaceuticals Limited 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TLX) 2026-08-20 - Seeking Alpha
Wed, 19 Aug 2026
Telix reports a $38 million after-tax profit; FY revenue and other income expected above $1 billion - Stock Titan
Wed, 19 Aug 2026
Press Release: Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 339 (M) |
| Shares Float | 273 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 297 (K) |
| Shares Short P.Month | 194 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.23 |
| Profit Margin | -0.9 % |
| Operating Margin | 1.9 % |
| Return on Assets (ttm) | 1.1 % |
| Return on Equity (ttm) | -1.9 % |
| Qtrly Rev. Growth | 49.2 % |
| Gross Profit (p.s.) | 1.12 |
| Sales Per Share | 2.37 |
| EBITDA (p.s.) | 0.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -566.5 |
| PEG Ratio | 0 |
| Price to Book value | 9.21 |
| Price to Sales | 4.77 |
| Price to Cash Flow | -222 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|